ライフサイエンスコーパス: TCID50

1 ved up to the maximum feasible dose (2x10(7) TCID50).

2 ectious virus produced by RPE cells (10(6.5) TCID50/0.1 ml) significantly surpassed levels produced b

3 rpassed levels produced by HEL cells (10(5.5)TCID50/0.1 ml).

4 han when given at the regular dose, 10(7.26) TCID50 (40 participants); as a control, a placebo vaccin

5 ncentrations ranging from 10(1.4) to 10(4.4) TCID50/5 microliters were capable of inducing both infla

6 the highest concentration of virus (10(4.4) TCID50/5 microliters) in CD-1 mice resulted in only the

7 ose escalation was performed from 104 to 107 TCID50 (50% tissue culture infectious dose).

8 CTL response when given at a dose of 10(8.0) TCID50 (60 participants) than when given at the regular

9 hem an easy and superior replacement for the TCID50 and other in vitro culture ID50 measures.

10 from 0.01 50% tissue culture infective dose (TCID50) and were able to detect at least 1 TCID50 of ent

11 nts treated at high-dose levels (10(8)-10(9) TCID50), and their median overall survival of 26.5 month

12 strain type 16 with a count of 100 using the TCID50 assay.

13 determined by RT-qPCR and virion release by TCID50 assay.

14 8 (HHV-8) 50% tissue culture infective dose (TCID50) assay using the T1H6-DC-SIGN cell line.

15 g the median tissue culture infectious dose (TCID50) assay.

16 HRV (1-10 TCID50/cell) significantly inhibited T cell proliferatio

17 to 10(9) 50% tissue culture infective doses (TCID50) consistently infected all the animals, and many

18 s, and many monkeys receiving 10(8) or 10(9) TCID50 developed paralysis.

19 A single 109 TCID50 dose of M2SR generated >=4-fold hemagglutination

20 The 5 x 105 TCID50 dose was superior to the 5 x 104 TCID50 dose, and

21 105 TCID50 dose was superior to the 5 x 104 TCID50 dose, and longer dosing intervals resulted in hig

22 1000 median tissue culture infectious dose (TCID50) dose produced moderate colds in most individuals

23 ction of immature dendritic cells at various TCID50 doses.

24 Only participants receiving 106 and 107 TCID50 experienced MMID at 44% and 40%, respectively.

25 immunodeficiency virus type 1 (HIV-1) and <1 TCID50 for simian immunodeficiency virus isolated from a

26 ml in the blood and between 10(6) and 10(10) TCID50/g tissue in the intestines, kidney, lungs, brain,

27 .5 log10 50% tissue culture infectious dose [TCID50]) in nasal wash viral titers and inflammation res

28 Viral antigen-specific ELISAs, qRT-PCR and TCID50 infectious assays were utilized to determine anti

29 166) were inoculated intranasally with 10(5) TCID50 influenza A/Texas/91 (H1N1) virus.

30 a-galactosidase, which was used to determine TCID50 levels.

31 e of 108 50% tissue culture infectious dose (TCID50) M2-deficient single replication (M2SR) influenza

32 9%-56.7%) of subjects following a single 108 TCID50 M2SR dose and among 80.6% (95% CI, 61.4%-92.3%) a

33 ingle high doses ranging from 10(7) to 10(9) TCID50 Mahoney type 1 virus were infected, and many of t

34 urine blood (EBOV concentration of 1 x 10(7) TCID50 . ml(-1)) at 4:1 vol/vol buffer/sample ratios.

35 issue culture infective dose per milliliter [TCID50 . ml(-1)]) and murine blood (EBOV concentration o

36 x 10(-3) 50% tissue culture infective doses (TCID50)/ml of cultured MERS-CoV per reaction.

37 4 x 10(2) 50% tissue culture infective dose (TCID50)/ml, as well as the no-virus negative-control sam

38 2 log10 50% tissue culture infectious doses (TCID50)/mL, respectively.

39 x 10(5) 50% tissue culture infective doses (TCID50)/ml.

40 Virus titers reached 10(8) TCID50/ml in the blood and between 10(6) and 10(10) TCID

41 suspension test with 0.25% NaOCl or EOW, the TCID50/mL was below the detection limit after 5 seconds.

42 tection (LOD) of 100 copies/reaction and 3.5 TCID50/mL, respectively.

43 50/mL, for a saturation value of ~4.801x10(3)TCID50/mL, with good repeatability and excellent specifi

44 tive results, was determined to be 4 x 10(2) TCID50/ml.

45 particles were detected in concentration 4.2 TCID50/mL.

46 rticles were detected in concentration <=4.2 TCID50/mL.

47 reatment groups was 137, 87.5, and 142 log10 TCID50/mL.h, respectively, and the median time to virus

48 ce challenged with a low virus dose at 10(3) TCID50/mouse.

49 e challenged with a high virus dose at 10(5) TCID50/mouse.

50 Three doses of 106.5 TCID50 of ALVAC-CMV(gB) induced very low neutralizing or

51 gative adults randomly received either 106.8 TCID50 of ALVAC-CMV(gB) or 106.8 TCID50 of ALVAC-RG, exp

52 ) vector expressing HIV-1MN gp160 or 10(5.5) TCID50 of ALVAC-rabies virus glycoprotein control at 0 a

53 ither 106.8 TCID50 of ALVAC-CMV(gB) or 106.8 TCID50 of ALVAC-RG, expressing the rabies glycoprotein,

54 tion against experimental challenge with 107 TCID50 of attenuated H1N1 (vaccine strain) by intranasal

55 Two doses of 10(7) TCID50 of ca influenza virus infected all infants, indic

56 ho were randomized to receive 10(6) or 10(7) TCID50 of canarypox (ALVAC) vector expressing HIV-1MN gp

57 (TCID50) and were able to detect at least 1 TCID50 of enterovirus in cerebrospinal fluid, stool, or

58 nuclear cells (PBMC) were challenged with 10 TCID50 of HIV-1MN or HIV-1BaL, titered in PBMC from norm

59 ety and immunogenicity of two doses of 10(7) TCID50 of live, attenuated cold-adapted (ca) influenza A

60 D50) of virus were estimated to be <1 and 10 TCID50 of MERS-CoV, respectively.

61 These data support the use of 10(8) TCID50 of MVA-BN in this population.

62 0 subjects received vaccine containing 10(8) TCID50 of MVA-BN, and 4 subjects received placebo.

63 by intraperitoneal (i.p.) injection of 10(5) TCID50 of SHRV/ml.

64 s received a single intranasal dose (10(6.2) TCID50) of ca A/Kawasaki/9/86 (H1N1) or ca A/Los Angeles

65 were randomized to receive 2 doses (108-109 TCID50) of M2SR or placebo administered 28 days apart.

66 10(7) median tissue culture infective doses (TCID50) of MVA-BN, 10 subjects received vaccine containi

67 in 10(6) 50% tissue culture infective doses (TCID50) of SHRV/ml, and adult zebrafish were susceptible

68 ID50) per 0.05 mL], medium dose [7.5 x 10(4) TCID50 per 0.25 mL], or high dose [3.0 x 10(5) TCID50 pe

69 ID50 per 0.25 mL], or high dose [3.0 x 10(5) TCID50 per 1.0 mL]), or the active comparator-Priorix.

70 10(4) median tissue culture infection doses (TCID50) per 0.05 mL], medium dose [7.5 x 10(4) TCID50 pe

71 city, median tissue culture infectious dose [TCID50] reduction, and immunofluorimetry) at different l

72 hy and 11 atopic asthmatic adults with 2,000 TCID50 RV-16.

73 l dose (LD50) was determined to be 0.015 50% TCID50 (tissue culture infective dose) of MARV/Ang-MA in

74 ybrid microchips was determined to be ~10(4) TCID50 titer/mL and 10(3)-10(4) EID50 titer/mL.

75 Validation of TCID50 values was performed by immunofluorescence assay

76 x 10(-2) 50% tissue culture infective doses (TCID50), was developed.